← Back to Search

Primary Care Practices for Opioid Use Disorder (RISE-OK Trial)

N/A
Recruiting
Led By Steven Crawford, MD
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 17
Awards & highlights

RISE-OK Trial Summary

This trialaims to develop a program to help manage pain and opioid use disorder in elderly and vulnerable adults, using innovative solutions and evidence-based quality improvement methods.

Who is the study for?
This trial is for older adults in Oklahoma with chronic pain, who may also be vulnerable due to disability or social factors. It's aimed at primary care practices and their staff willing to implement a new opioid management program. Patients under 18, those not suffering from chronic pain, and practices without electronic health records are excluded.Check my eligibility
What is being tested?
The study tests a comprehensive opioid management program in primary care settings for the elderly. The approach includes multi-modal pain treatment, patient-centered care, and evidence-based improvements using implementation science to optimize pain management.See study design
What are the potential side effects?
Since this trial focuses on dissemination and implementation research rather than direct medical interventions like drugs or surgeries, it does not have typical side effects. However, changes in opioid use could affect patients' experience of pain relief.

RISE-OK Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 17
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 17 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Health-Related Quality of Life and Functioning: Mental Health Summary Score
Health-Related Quality of Life and Functioning: Physical Health Summary Score
Morphine Milligram Equivalent (MME)
Secondary outcome measures
Chronic Opioid Therapy Statistics: Chronic Pain Diagnosis
Chronic Opioid Therapy Statistics: Eligible Patients
Chronic Opioid Therapy Statistics: High Risk Patients
+6 more

RISE-OK Trial Design

1Treatment groups
Experimental Treatment
Group I: Primary Care PracticesExperimental Treatment1 Intervention
Dissemination and Implementation Research

Find a Location

Who is running the clinical trial?

Agency for Healthcare Research and Quality (AHRQ)FED
398 Previous Clinical Trials
6,817,724 Total Patients Enrolled
University of OklahomaLead Sponsor
455 Previous Clinical Trials
97,266 Total Patients Enrolled
Steven Crawford, MDPrincipal InvestigatorUniversity of Oklahoma

Media Library

Primary Care Practices Clinical Trial Eligibility Overview. Trial Name: NCT05037682 — N/A
Opioid Use Disorder Research Study Groups: Primary Care Practices
Opioid Use Disorder Clinical Trial 2023: Primary Care Practices Highlights & Side Effects. Trial Name: NCT05037682 — N/A
Primary Care Practices 2023 Treatment Timeline for Medical Study. Trial Name: NCT05037682 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants can potentially join this research project?

"Affirmative, the information available on clinicaltrials.gov denotes that this experiment is currently recruiting patients. It was first published on September 30th 2020 and most recently modified on November 21st 2022. The trial necessitates 1035 participants from a single site to be recruited."

Answered by AI

What is the ultimate aim of this research endeavor?

"This trial has a duration of 17 months and its primary endpoint is the Morphine Milligram Equivalent (MME). Secondary endpoints include Chronic Opioid Therapy Statistics: Chronic pain Diagnosis, Diversification of Pain Therapy, and Pain-Function Interference which are expressed respectively as % of patients on chronic opioids with a chronic pain diagnosis; Number (and Type) of pharmacological and non-pharmacological treatment types; 3-item Pain-Enjoyment-General Activity (PEG) score."

Answered by AI
Recent research and studies
~129 spots leftby Sep 2024